anti-VEGF
Choice of anti VEGF agents for wet AMD treatments
College Statement Ophthalmologists have a choice of two anti-VEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). Photodynamic therapy is also licensed and approved and still has a role in a small subset of patients. An anti-VEGF agent is generally used for the treatment of wet AMD
Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly
College Statement This statement refers only to injections of anti –Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly directly through the conjunctiva and sclera using a sharp needle. This statement is the current College position and supersedes older statements on intraocular injections in the ARMD Guidelines for Management (2009) and Maximising Capacity in AMD Services